Reunion Neuroscience Inc C.FTRP

Primary Symbol: T.REUN

Healthcare Biotechnology

Reunion Neuroscience Inc. is engaged in the psychedelic drug development company that provides therapeutic solutions for mental health conditions by developing serotonin receptor agonist compounds. The Company is developing the advancement of synthetic molecules targeting serotonin 5HT2A receptors. The Company’s products include RE104 and RE200. The Company’s lead asset, RE-104, which is a psychedelic drug being developed for post-partum and treatment resistant depression as a potential fast-acting antidepressant with durable efficacy. The RE104 as a potentially fast-acting treatment for the key indications of postpartum and treatment resistant depression. The Company is developing the RE200 series, which includes compounds with potential for more selective serotonin receptor activity with reduced psych activity for potential use in more chronic treatment paradigms and indications. The Company is focused on the research and development of its RE200 molecule group.

TSX:REUN - Post by User

Reunion Neuroscience Inc

<< Previous

Bullboard Posts

Next >>

Post by evilballson Feb 16, 2021 11:21pm

348 Views

Post# 32581703

MD & A says it all...

20 to 30 clinics opend up by this time next year. I have heard average revenue once fully operational in excess of $1M per year
Also have synthetic psilocybin that lasts half the duration being set up to go through trials.
Selling truffles in the Netherlands.
Mushroom farm in Jamaica.
Developing IP for therapies including an app.
Apart of MAPS trials
These guys are definitely setting the gold standard.